Nasus Pharma
Powder-based Intra-nasal Products
Startup Public Health Tech & Life Sciences Est. 2019
🌐 WebsiteLinkedIn
Total Raised
$10M
Public
Last Round
$10M
1 rounds
Team
5
1-10 employees
Confidence
90/100
News
13
articles
Patents
1
About
Nasus Pharma is developing a number of intranasal powder products aimed at assisting patients in several acute emergency situations (such as opioid overdose and anaphylactic shock) based on its microsphere technology. Nasus's portfolio comprises a number of programs including intranasal naloxone, intranasal epinephrine, and a number of preclinical proof-of-concept programs.
Classification
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrug Delivery
Core Technology
Materials & Substances
Target Customer
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business Model
B2B2C
Tags
drug-deliverynon-invasivemedical-technologiesemergency-responsepharmaceuticalstreatmentsrespiratorybiopharmaceuticalinhalationbacteriamedical-devicespublic-health
Funding & Events
Aug 2025
Exit Undisclosed
News (13)
Oct 8, 2025 · finance.yahoo.com
growth-positive
Nasus Pharma Announces Expanded Agreement to Support Development and Commercialization of NS002 Intranasal Epinephrine Program
Product StagePartners
Sep 2, 2025 · finance.yahoo.com
growth-positive
Nasus Pharma Announces Upcoming Presentation at H.C. Wainwright 27th Annual Global Investment Conference
Product StageManagement Changes
Aug 26, 2025 · finance.yahoo.com
growth-positive
Nasus Pharma Marks NYSE American Listing with Bell Ringing Ceremony
Public Trading
Aug 14, 2025 · finance.yahoo.com
growth-positive
Nasus Pharma Announces Closing of Initial Public Offering
Public TradingProduct StageInvestment
Aug 13, 2025 · finance.yahoo.com
growth-positive
Nasus Pharma Announces Pricing of $10 Million Initial Public Offering
Public Trading
Aug 13, 2025 · en.globes.co.il
growth-positive
Israeli co Nasus Pharma completes Wall Street IPO
Public TradingInvestment
Feb 27, 2025 · www.prnewswire.com
growth-positive
/PRNewswire/ -- Nasus Pharma Ltd. ("Nasus Pharma" or the "Company"), a clinical-stage biopharmaceutical company focused on developing needle-free, powder-based...
Product Stage
Mar 17, 2021 · www.prnewswire.co.uk
growth-positive
Safety of Taffix reaffirmed
Customers
Mar 16, 2021 · www.dailymail.co.uk
growth-negative
Spanish regulators BAN £51 nasal spray that may cut risk from Covid
Customers
Oct 14, 2020 · www.calcalistech.com
growth-positive
Nasal spray to stop spread of Covid-19? Israeli pharma company puts its product to the test
Customers
Sep 30, 2020 · www.jpost.com
growth-positive
https://www.jpost.com/health-science/israeli-pharma-pioneer-introduces-taffix-antiviral-nose-powder-644001
Customers
Jul 9, 2020 · www.hospimedica.com
growth-positive
Innovative Nasal Powder Inhaler Blocks More than 99% of SARS-CoV-2 Viruses from Reaching Nasal Mucosa in Studies
Customers
Jul 7, 2020 · www.globenewswire.com
growth-positive
Nasus Pharma Announces Data Demonstrating Efficacy of TaffiX® Intranasal Antiviral Protection Against SARS-CoV-2
CustomersPartners
Details
Product Stage
Released
Employees
1-10
Exact Count
6
District
Center District
Founded
2019
Registrar
516022712
Crunchbase
nasus-pharma-ltd
Locations
Menachem Begin Road 48, Tel Aviv-Yafo, Israel
Links
Website
www.nasuspharma.com/
LinkedIn
Profile
Admin
Last Update
Oct 8, 2025
Verified by
Hilla Gorokhovsky
Missing
funding rounds, markets, not claimed
Team (5)
Udi Gilboa
Co-founder & Chairman
Founder
Dr. Dalia Meggido
Co-founder, CEO & Board Member
Founder
Tair Lapidot
VP R&D and Clinical Development
Iris Erez
Commercial And Marketing Director
Carolina Abrutzky
Director of CMC
Internal
Created by
Yotam Maman (yotamm1988@gmail.com)
Created
2020-07-27T00:00:00.000Z
Last editor
Matan Eblagon (matane@sncentral.org)
Status
Public on NYSE on Aug, 2025;
Finder · Nasus Pharma · 2026